Early onset familial Alzheimer’s disease is a rare form of dementia caused by genetic mutations that can strike people in their 30s, 40s, or 50s, long before most individuals expect to face memory loss or cognitive decline.

Understanding Treatment Goals in Early Onset Familial Alzheimer’s

When someone develops early onset familial Alzheimer’s disease, the main goal of treatment is to help manage symptoms and maintain quality of life for as long as possible. Treatment focuses on slowing down the progression of cognitive decline, addressing behavioral changes, and supporting the person’s ability to function in daily life. Because this condition strikes younger people—often while they’re still working, raising children, or caring for their own aging parents—the impact extends far beyond memory loss alone.^[1]

The approach to treating early onset familial Alzheimer’s disease depends on several factors, including the stage of the disease when it’s diagnosed, which genetic mutation is involved, and the specific symptoms each person experiences. Some people may have more trouble with memory, while others struggle more with language, decision-making, or behavioral changes. This means treatment plans need to be tailored to each individual’s unique situation.^[3]

Currently, there is no cure for early onset familial Alzheimer’s disease. However, medical societies have approved certain medications that can help manage symptoms, and researchers continue to investigate new therapies through clinical trials. These ongoing studies offer hope that future treatments may better target the underlying causes of the disease rather than just addressing symptoms.^[10]

Standard Treatment Approaches

The standard treatment for early onset familial Alzheimer’s disease includes several types of medications that have been approved by medical authorities. These drugs work by affecting chemicals in the brain that are important for memory and thinking. While they cannot stop or reverse the disease, they may help slow down symptom progression and improve quality of life for some people.^[10]

Cholinesterase Inhibitors

One major category of medications used in early onset familial Alzheimer’s disease is called cholinesterase inhibitors. These drugs include donepezil, rivastigmine, and galantamine. They work by blocking an enzyme called acetylcholinesterase, which normally breaks down a chemical messenger in the brain called acetylcholine. By preventing this breakdown, these medications increase the amount of acetylcholine available in the brain, helping neurons communicate better with each other.^[10]

These medications are considered effective for managing symptoms related to memory, reasoning, and learning. People taking cholinesterase inhibitors may experience improvements in their ability to think clearly, remember recent events, and perform daily activities. However, the degree of improvement varies from person to person, and these drugs work better for some individuals than others.

The most common side effects of cholinesterase inhibitors include nausea, vomiting, diarrhea, loss of appetite, and muscle cramps. These side effects are usually mild and may improve over time as the body adjusts to the medication. Doctors typically start with a low dose and gradually increase it to minimize side effects while finding the most effective dose for each person.

NMDA Receptor Antagonists

Another type of medication used in Alzheimer’s treatment is memantine, which belongs to a class called NMDA receptor antagonists. This drug works differently from cholinesterase inhibitors. It blocks receptors in the brain called N-methyl-D-aspartate (NMDA) receptors and reduces excess levels of a chemical called glutamate. When there’s too much glutamate in the brain, it can promote the death of neurons. By blocking this process, memantine may help slow certain degenerative processes associated with Alzheimer’s disease.^[10]

Memantine is particularly useful for people in the moderate to severe stages of Alzheimer’s disease, though it can also be prescribed for those in earlier stages. Side effects are generally mild and may include dizziness, headache, confusion, and constipation. Like cholinesterase inhibitors, memantine cannot cure the disease but may help manage symptoms and slow progression.

Combination Therapy

Many doctors recommend using both a cholinesterase inhibitor and memantine together, which is called combination therapy. Research suggests that combination therapy may be more effective than using just one medication alone. By targeting different chemical pathways in the brain, these medications can provide complementary benefits and potentially offer better symptom control.^[10]

Treatment duration for these standard medications typically continues for as long as they provide benefit. Some people may take these drugs for several years, while others may find that the benefits decrease over time as the disease progresses. Doctors monitor patients regularly to assess whether the medications are still helping and to adjust doses or switch medications if needed.

Disease-Modifying Drugs

A newer category of medications called disease-modifying drugs has been developed to target the underlying biological processes of Alzheimer’s disease. These include medications like aducanumab, lecanemab, and donanemab. These drugs work by reducing amyloid-beta proteins in the brain—sticky protein fragments that accumulate and form clumps called plaques, which are a hallmark of Alzheimer’s disease.^[10]

These medications prevent amyloid-beta from accumulating and disrupting neuron function. Because they target a fundamental cause of Alzheimer’s rather than just treating symptoms, they have the potential to slow disease progression. However, their effectiveness varies among patients, and ongoing clinical trial research continues to evaluate their benefits and risks. Due to their potential to slow disease progression, these medications have been approved specifically for early-stage Alzheimer’s disease, including early onset forms.

The side effects of disease-modifying drugs can be more significant than those of standard medications. They may include brain swelling (called ARIA-E, or amyloid-related imaging abnormalities-edema) or small brain bleeds (called ARIA-H, or amyloid-related imaging abnormalities-hemorrhage). Because of these potential complications, people taking these medications require regular brain imaging scans to monitor for side effects.

Promising Treatments Being Tested in Clinical Trials

Beyond standard treatments, researchers are actively testing new and innovative therapies in clinical trials. These studies are crucial for developing better treatment options for people with early onset familial Alzheimer’s disease. Clinical trials happen in different phases, each designed to answer specific questions about a new treatment’s safety and effectiveness.

Understanding Clinical Trial Phases

Phase I trials focus primarily on safety. Researchers give the experimental treatment to a small group of people to determine if it causes any serious side effects and to find the right dose. These trials help establish whether it’s safe enough to continue testing the treatment in larger groups.^[3]

Phase II trials examine whether the treatment actually works—this is called evaluating efficacy. Researchers give the treatment to a larger group of people who have the disease and carefully monitor whether it improves symptoms, slows disease progression, or shows other beneficial effects. They also continue watching for side effects to make sure the treatment remains safe.

Phase III trials are large studies that compare the new treatment with standard treatments or a placebo (an inactive substance). These trials involve hundreds or even thousands of people and provide the strongest evidence about whether a new treatment should be approved for widespread use. Researchers look at how well the treatment works, how it compares to existing options, and whether the benefits outweigh any risks.

Gene Therapy Approaches

One exciting area of research involves gene therapy—treatments designed to address the genetic mutations that cause early onset familial Alzheimer’s disease. Since this form of Alzheimer’s is caused by mutations in specific genes (presenilin 1, presenilin 2, or amyloid precursor protein), researchers are exploring ways to correct or compensate for these genetic errors.^[1]

Gene therapy might work by delivering healthy copies of genes into brain cells, turning off faulty genes, or editing the genetic code to fix mutations. These approaches are still in early stages of development, with most still in laboratory research or early-phase clinical trials. The goal is to intervene at the most fundamental level—the genetic cause of the disease—rather than just treating symptoms that appear later.

Innovative Molecular Therapies

Scientists are testing various molecules designed to target specific pathways involved in Alzheimer’s disease. Some of these experimental treatments focus on preventing the production of toxic amyloid-beta protein fragments. Others aim to stop tau proteins from twisting into harmful tangles inside brain cells. Still others work to reduce inflammation in the brain, which is thought to contribute to neuron damage.^[3]

These innovative therapies often have code names during development (like MK-2214 or DNL593) before they receive official drug names. Each one works through a unique mechanism of action. For example, some drugs might block specific enzymes that produce amyloid-beta, while others might enhance the brain’s ability to clear away toxic proteins. Some experimental treatments work by protecting neurons from damage or helping them repair themselves.

Immunotherapy and Antibody Treatments

Another promising approach involves using immunotherapy—treatments that harness the body’s immune system to fight Alzheimer’s disease. Many of these therapies use specially designed antibodies (proteins that can recognize and bind to specific targets) to identify and remove amyloid-beta proteins or tau tangles from the brain.^[10]

Several antibody treatments have shown promising results in clinical trials. Some have demonstrated the ability to reduce amyloid plaques in the brain and slow cognitive decline in people with early Alzheimer’s disease. Researchers continue to refine these approaches to make them more effective and reduce side effects.

Enzyme Inhibitors and Receptor Modulators

Clinical trials are also testing medications called enzyme inhibitors that block specific enzymes involved in creating toxic proteins in the brain. Other experimental drugs work as receptor modulators, meaning they adjust how certain receptors on brain cells respond to chemical signals. By fine-tuning these communication pathways, researchers hope to prevent or slow the cascade of events that leads to neuron death in Alzheimer’s disease.

Preliminary Results from Recent Trials

Some clinical trials have reported encouraging preliminary results. For instance, certain antibody treatments have shown improvement in clinical parameters such as cognitive test scores and measures of daily functioning. Some experimental therapies have demonstrated positive safety profiles with manageable side effects. Other trials have reported success in reducing the amount of toxic proteins in the brain, as measured by brain imaging or spinal fluid tests.

However, it’s important to understand that preliminary results don’t guarantee that a treatment will ultimately prove effective. Many promising therapies in early trials don’t show the same benefits in larger Phase III studies. This is why researchers must carefully complete all phases of testing before a new treatment can be approved for general use.

Most Common Treatment Methods

• Cholinesterase Inhibitors
  • Donepezil, rivastigmine, and galantamine block acetylcholinesterase enzyme to increase acetylcholine levels
  • Help improve memory, reasoning, and learning abilities
  • Common side effects include nausea, vomiting, diarrhea, and loss of appetite
• NMDA Receptor Antagonists
  • Memantine blocks NMDA receptors and reduces excess glutamate
  • May help slow degenerative processes and manage moderate to severe symptoms
  • Side effects include dizziness, headache, confusion, and constipation
• Combination Therapy
  • Uses both cholinesterase inhibitors and memantine together
  • May be more effective than using a single medication alone
  • Targets different chemical pathways in the brain for complementary benefits
• Disease-Modifying Drugs
  • Aducanumab, lecanemab, and donanemab reduce amyloid-beta proteins in the brain
  • Prevent protein accumulation and disruption of neuron function
  • Approved for early-stage Alzheimer’s disease including early onset forms
  • Require regular brain imaging to monitor for potential side effects like brain swelling or bleeding
• Gene Therapy (Experimental)
  • Addresses genetic mutations that cause early onset familial Alzheimer’s disease
  • May involve delivering healthy genes, turning off faulty genes, or editing genetic code
  • Still in early stages of development and testing
• Immunotherapy
  • Uses antibodies to identify and remove toxic proteins from the brain
  • Some treatments have shown ability to reduce amyloid plaques and slow cognitive decline
  • Ongoing refinement to improve effectiveness and reduce side effects
• Enzyme Inhibitors and Receptor Modulators (Experimental)
  • Block specific enzymes involved in creating toxic proteins
  • Adjust how brain cell receptors respond to chemical signals
  • Aim to prevent or slow the cascade of events leading to neuron death